Noul노을
376930 · KOSDAQ · ₩376930 · 노을
- Market cap
- ₩22B
- Enterprise value
- ₩20B
- P/E
- —
- P/B
- 1.4×
- Dividend yield
- 0.0%
- ROE
- −119.7%
- Net margin
- −537.6%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−86.4% from the high
₩1,151Today: ₩2,170 – ₩2,170₩15,924
Returns
- 1W+56.2%
- 1M+39.9%
- 3M−30.4%
- 6M−74.9%
- YTD−77.9%
- 1Y−82.7%
- Volume today
- 114,595
- 1.6× the 20-day average
- Traded today
- ₩249M
- Listed shares
- 10,258,264
- EPS (12 months)
- −₩1,917
- Earnings yield −88.3%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+29.9% on Oct 26, 2026. Trading value 2.4× its normal.
Noul has filed a notice about delisting, which means its shares may be removed from the stock exchange. The filing itself is the only source, so there is little other context about what it means for the company's future.
AI summary of the news and filings linked. It can be wrong; check them.
- • Filing: Delisting
- • Filing: Rights offering (paid-in capital increase) decision
- • Foreign investors sold a net ₩6.4M that day
- • Buzz 56 on JONBUR: heavy trading
Possible reasons, not certainties. Not financial advice.
Signals
Normal- BuzzNormalBuzz 56: heavy trading.
- SentimentNegativeNews: A delisting filing is a serious negative step for a listed company. Community: 0 bullish, 0 bearish posts this week.
- MomentumStrong32.2% over the last month; the price is above its 20-day average.
- News impactHigh3 news items and filings in two weeks; 3 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Noul stock overview
Noul (노을, KRX: 376930) is listed on KOSDAQ, in the Medical & precision devices sector. The company produces and sells miLab, an on-device AI solution for blood and cancer diagnostics that automates microscopy-based pathology tests, aiming to bring diagnostic lab capability to settings without specialist staff or IT infrastructure. Its shares closed at ₩2,170 on Oct 26, 2026, up 29.94% on the day, giving it a market value of ₩22B.
Key facts
- Market cap
- ₩22B
- Sector
- Medical & precision devices
- Latest price change
- +29.94%
- As of
- Oct 26, 2026
- Main business
- The company produces and sells miLab, an on-device AI solution for blood and cancer diagnostics that automates microscopy-based pathology tests, aiming to bring diagnostic lab capability to settings without specialist staff or IT infrastructure.
Quick answers about Noul
- What does Noul do?
- The company produces and sells miLab, an on-device AI solution for blood and cancer diagnostics that automates microscopy-based pathology tests, aiming to bring diagnostic lab capability to settings without specialist staff or IT infrastructure. Its products include cartridges and a platform for malaria, peripheral blood smear, and cervical cell analysis, sold mainly to small and mid-sized diagnostic labs and reference institutions worldwide, with operations and product registrations across Africa, Asia, Europe, Latin America, and the United States.
- What is the market cap of Noul?
- The market capitalisation of Noul was ₩22B at the close on Oct 26, 2026.
- Who are the largest shareholders of Noul?
- According to the latest official filings, the largest reported holders are MSEED,INC. (10.37%, as of Sep 10, 2026); Kim Kyung-hwan (2.92%, as of Sep 10, 2026); Im Chan-yang (2.92%, as of Sep 10, 2026).
- When is the next earnings report from Noul?
- Korean companies rarely announce results dates in advance. Based on when Noul filed the same report in past years, its next preliminary results is expected between Apr 2, 2026 and Nov 4, 2026.
Company profile
The company produces and sells miLab, an on-device AI solution for blood and cancer diagnostics that automates microscopy-based pathology tests, aiming to bring diagnostic lab capability to settings without specialist staff or IT infrastructure. Its products include cartridges and a platform for malaria, peripheral blood smear, and cervical cell analysis, sold mainly to small and mid-sized diagnostic labs and reference institutions worldwide, with operations and product registrations across Africa, Asia, Europe, Latin America, and the United States.
Written by AI from the company's latest annual report.
- Korean name
- 노을
- Themes
- AI healthcare
- CEO
- 임찬양(단독 대표이사)
- Founded
- Dec 2015
- Listed
- Mar 2022
- Listed shares
- 10,258,264
- Fiscal year ends
- Month 12
- Website
- noul.com
Similar companies
- TSE131290 · ₩2.7T₩241,000−6.23%
- Classys214150 · ₩1.8T₩27,200−1.98%
- Kctech281820 · ₩1.7T₩86,400−8.67%
- Park Systems140860 · ₩1.6T₩223,000−6.30%
- Seers458870 · ₩1.1T₩27,850+17.51%
- DI003160 · ₩1T₩36,100−3.35%
- Curiox Biosystems445680 · ₩1T₩58,700−2.17%
- LivsMed491000 · ₩923B₩36,550−3.82%
Recent filings
See all- DelistingOct 26, 2026
- Rights offering (paid-in capital increase) decisionOct 23, 2026
- Other Market Notice (Additional Concern of Designation as Administrative Issue) (Market Capitalization Below ₩20B)Oct 14, 2026
- 5%+ holding reportSep 10, 2026
- Insider shareholding reportSep 10, 2026
Titles in Korean until English translations are added.
Also known as: Noul / 노을 / 376930 / KRX:376930
Source: KRX statistical information